CCNG2 and pancreatic neoplasm: Previous expression analysis allowed for the identification of miR-1246 from gemcitabine-resistant pancreatic cancer cells, with high expression in pancreatic cancer, but abnormal counterparts and subsequent analysis using expression profiling of pancreatic cancer cells demonstrated that cyclin G2 [92] is the target of miR-1246 in the downstream networks [93].